Professor Karim Fizazi and Professor Nicholas James discuss data presented at the 2018 Genitourinary Cancers Symposium as well as the current landscape and the future for the treatment and management of patients with metastatic hormone sensitive prostate cancer (mHSPC)
They discuss what guides treatment choices for these patients and the factors that influence this decision including patient choice, toxicitiy and the efficacy data for abiraterone and docetaxel.
The discussion looks to the future for patients with mHSPC with conversations around the STAMPEDE and PEACE1 trials.
This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).
Video credits to the YouTube channel owner